[{"data":1,"prerenderedAt":185},["ShallowReactive",2],{"content-route-/en/research/sifo-colectomy-aspirate-2018":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":167,"alternates":176},"target","/en/research/sifo-colectomy-aspirate-2018","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":69,"body":73},"SIBO and SIFO after colectomy: one selected study","A selected cohort found total SIFO in 14/50 versus 6/50 (p=0.08); the mixed SIBO/SIFO difference does not establish SIFO risk or antifungal benefit.","2026-10-09","First publication of a selected-cohort summary; no claim or practical action changed.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":43,"limitations":52,"practicalChange":68},"rao-colectomy-sifo-2018","Single-center controlled comparison with consecutive recruitment and nonrandomized treatment follow-up","Adults referred for persistent unexplained gastrointestinal symptoms to a specialist motility center; 50 had a prior colectomy and 50 symptomatic controls had no colectomy.","100 adults (50 per group); duodenal aspirates were obtained from 35 colectomy patients and 32 controls, and glucose breath tests from 48 in each group.","contextual","This selected cohort adds an example of aspirate-defined SIFO and a mixed SIBO/SIFO finding, but total SIFO was not significantly different between groups. The mixed category is not total SIFO, and the study does not establish SIFO risk, symptom discrimination, or antifungal benefit.","/en/research/evidence/broad-candida-claims","The paper reports no financial support.","The authors reported no potential competing interests.","2018-04-25",[38,39,40,41,42],"SIBO, defined by positive glucose breath test or duodenal culture, was reported in 31/50 (62%) patients after colectomy and 16/50 (32%) controls (p=0.005). This is a SIBO result, not a SIFO risk estimate.","Total SIFO was reported in 14/50 (28%) patients after colectomy and 6/50 (12%) controls (p=0.08, not statistically significant). Mixed SIBO/SIFO was 12/50 (24%) versus 4/50 (8%) (p=0.017). SIFO alone occurred in 2/50 people in each group; the mixed result is not total SIFO.","Duodenal aspirates were obtained from 35/50 colectomy patients and 32/50 controls; glucose breath testing was performed in 48/50 in each group. The article reports the SIFO totals using the full group denominators.","At a three-month visit or telephone follow-up, 74% of patients with pooled SIBO/SIFO after colectomy and 69% of controls reported improvement (p=0.69); mean satisfaction scores were 61% versus 42%. Treatments varied and were not randomized or blinded.","Among the two people with SIFO alone in each group, individual reported improvement was 70% and 0% after colectomy, and 33% and 50% in controls; no p-values were reported for these four people.",{"appliesTo":44,"doesNotApplyTo":47},[45,46],"The selected adult referral population with chronic unexplained gastrointestinal symptoms and prior colectomy or no bowel surgery.","What this one study reports about aspirate-defined SIFO, mixed SIBO/SIFO, and uncontrolled follow-up in that setting.",[48,49,50,51],"General-population SIFO prevalence or evidence that colectomy increases SIFO risk.","Diagnosing SIFO from symptoms, or using the mixed-overgrowth result as the total SIFO result.","Antifungal treatment benefit, durable symptom improvement, fungal eradication, or safety.","Broad whole-body or self-diagnosed Candida-overgrowth claims.",[53,56,59,62,65],{"finding":54,"limitation":55},"The cohort included 50 patients with colectomy and 50 symptomatic controls at one specialist center.","Referral and selection effects limit generalization; the cohort does not estimate population prevalence or establish a causal risk factor.",{"finding":57,"limitation":58},"The reported total SIFO comparison was 14/50 versus 6/50, while mixed SIBO/SIFO was 12/50 versus 4/50 and SIFO alone was 2/50 per group.","The total-SIFO difference was not statistically significant, and the significant mixed category cannot be substituted for total SIFO or interpreted as a SIFO risk estimate.",{"finding":60,"limitation":61},"Duodenal aspirates were obtained from 35 colectomy patients and 32 controls, while the reported SIFO totals use 50-person group denominators.","SIFO was identified only through aspirate culture, and the fungal-growth threshold of at least 10^3 CFU/mL is not broadly standardized.",{"finding":63,"limitation":64},"Patients received varied antibiotics and/or antifungals, with improvement reported for pooled SIBO/SIFO groups.","Treatment was nonrandomized and unblinded, no repeat aspirate or fungal-eradication endpoint was collected, no adverse-outcome accounting was reported, and the SIFO-only subgroup had only two people per group.",{"finding":66,"limitation":67},"Baseline symptom scores were compared by colectomy status.","Those comparisons do not validate symptom discrimination by SIFO status; the study does not establish symptoms as a way to identify SIFO.","No practical change. The study adds context but does not establish SIFO risk after colectomy, symptom-based identification, antifungal benefit, eradication, or safety.",[70],{"group":71,"route":33,"label":72},"evidence","Broad Candida claims evidence map",{"type":74,"value":75,"toc":163},"minimark",[76,84,90,96,102,111,117,126,132,138,144],[77,78,80],"content-section",{"section-key":10,"title":79},"Bottom line",[81,82,83],"p",{},"In this selected cohort, total SIFO was 14/50 after colectomy and 6/50 among controls (p=0.08, not statistically significant). Mixed SIBO/SIFO was 12/50 versus 4/50 (p=0.017), while SIFO alone occurred in 2/50 people in each group. The mixed result is not total SIFO and does not establish SIFO risk or antifungal benefit.",[77,85,87],{"section-key":11,"title":86},"Why this source matters",[81,88,89],{},"The study adds a second selected symptomatic cohort to the small literature on aspirate-defined SIFO. Its results make it important to keep total SIFO separate from mixed bacterial and fungal overgrowth when describing the findings.",[77,91,93],{"section-key":12,"title":92},"Study and population",[81,94,95],{},"This single-center comparison recruited consecutive adults over three years at a specialist gastrointestinal motility center. All had more than a year of unexplained gastrointestinal symptoms after routine evaluation. Fifty had undergone colectomy; 50 symptomatic controls had no colectomy. Three additional colectomy patients and two controls were excluded for reasons including small-bowel surgery, pseudo-obstruction, scleroderma, or a blind loop after bariatric surgery.",[77,97,99],{"section-key":13,"title":98},"What was tested",[81,100,101],{},"The investigators compared prior colectomy with no colectomy. SIBO was defined by bacterial culture at or above 10^3 CFU/mL or a positive glucose breath test. SIFO was defined by fungal growth at or above 10^3 CFU/mL in a duodenal aspirate. A sterile catheter was passed to the third or fourth portion of the duodenum to collect 3–5 mL for aerobic, anaerobic, and fungal culture; fungal plates were held for four weeks.",[77,103,105,108],{"section-key":14,"title":104},"Results",[81,106,107],{},"The paper reported SIBO in 31/50 (62%) colectomy patients and 16/50 (32%) controls (p=0.005). Total SIFO was 14/50 (28%) and 6/50 (12%), respectively (p=0.08, not statistically significant). Mixed SIBO/SIFO was 12/50 (24%) versus 4/50 (8%) (p=0.017); SIFO alone occurred in 2/50 people in each group. These are separate outcomes: the mixed category must not be treated as total SIFO.",[81,109,110],{},"At three months, 74% of patients with pooled SIBO/SIFO after colectomy and 69% of controls reported improvement (p=0.69), with mean satisfaction scores of 61% and 42%. This follow-up combined different bacterial and fungal diagnoses and different, individually selected treatments.",[77,112,114],{"section-key":15,"title":113},"Applicability",[81,115,116],{},"These findings apply to a highly selected group of adults with chronic unexplained gastrointestinal symptoms evaluated at one specialist center. They do not estimate SIFO prevalence in the general population or show that colectomy increases SIFO risk. The mixed SIBO/SIFO comparison does not replace the nonsignificant total-SIFO result.",[77,118,120,123],{"section-key":16,"title":119},"Limitations",[81,121,122],{},"The study was single-center and the authors noted referral bias. Aspirates were obtained from 35 colectomy patients and 32 controls, while the paper reports total SIFO using the full groups of 50; the SIFO culture threshold is not broadly standardized. The SIFO-only subgroup contained two people per group.",[81,124,125],{},"Treatment was not randomized or blinded. Antibiotics and antifungals varied, outcomes pooled SIBO with SIFO, there was no repeat aspirate to check eradication, and adverse outcomes were not reported. The observed response therefore does not estimate an antifungal effect or establish treatment safety. Baseline symptom scores were reported by colectomy group, not as a validated test of symptom discrimination by SIFO status.",[77,127,129],{"section-key":17,"title":128},"Contribution to the evidence",[81,130,131],{},"Contextual. The study adds a selected aspirate-based cohort but does not change the current conclusion that SIFO is a narrow research entity with limited evidence. Total SIFO was not significantly different; the mixed-overgrowth result does not establish SIFO risk, symptom discrimination, or treatment benefit.",[77,133,135],{"section-key":18,"title":134},"Practical change",[81,136,137],{},"No practical change. This uncontrolled cohort does not establish that colectomy causes SIFO, that symptoms identify SIFO, or that antifungal treatment produces durable benefit or eradication. It does not support a change in testing or treatment advice.",[77,139,141],{"section-key":19,"title":140},"Funding and conflicts",[81,142,143],{},"The paper reports no financial support. The authors report no potential competing interests.",[77,145,147],{"section-key":20,"title":146},"Source",[81,148,149,156,157,162],{},[150,151,155],"a",{"href":152,"rel":153},"https://pmc.ncbi.nlm.nih.gov/articles/PMC5915536/",[154],"nofollow","Read the original article"," (published 25 April 2018; ",[150,158,161],{"href":159,"rel":160},"https://doi.org/10.1038/s41424-018-0011-x",[154],"DOI: 10.1038/s41424-018-0011-x","). The full text is available from PubMed Central.",{"title":164,"searchDepth":165,"depth":165,"links":166},"",2,[],{"sources":168,"claims":174,"safety":175},[169],{"sourceId":27,"title":170,"canonicalId":171,"canonicalUrl":152,"publisher":172,"sourceType":173,"publicationDate":36,"lastChecked":24},"Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)?","PMID:29691369; DOI:10.1038/s41424-018-0011-x","Clinical and Translational Gastroenterology","observational-study",[],[],[177,180,183],{"rel":178,"hreflang":6,"href":179},"alternate","https://candipedia.org/en/research/sifo-colectomy-aspirate-2018/",{"rel":178,"hreflang":181,"href":182},"pl-PL","https://candipedia.org/pl/research/sifo-kolektomia-aspirat-2018/",{"rel":178,"hreflang":184,"href":179},"x-default",1794951397578]